预约演示
更新于：2025-12-18
Levofloxacin
左氧氟沙星
更新于：2025-12-18
概要
基本信息
简介该药对革兰氏阳性和阴性细菌均有效，包括那些对其他抗生素产生耐药性的细菌。这个特性使得它成为治疗多药耐药菌引起的严重感染的选择。 |
药物类型 小分子化药 |
别名 (-)-Ofloxacin、(S)-Ofloxacin、L-Ofloxacin + [136] |
作用方式 抑制剂 |
作用机制 Bacterial DNA gyrase 抑制剂(细菌DNA旋转酶 抑制剂)、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C36H42F2N6O9 |
InChIKeySUIQUYDRLGGZOL-RCWTXCDDSA-N |
CAS号138199-71-0 |
关联
395
项与 左氧氟沙星 相关的临床试验NCT07240077
Beta-lactam Monotherapy Versus Beta-lactam Plus Levofloxacin for the Treatment of Streptococcal Bacteremia: A Multicenter, Randomized, Double-Blind, Pragmatic Trial
NCT07021729
Comparison of Conventional Clarithromycin Vs Alternative Levofloxacin Based Regimen in Treatment of Helicobacter Pylori Infection
CTIS2024-516232-10-00
Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.
100 项与 左氧氟沙星 相关的临床结果
登录后查看更多信息
100 项与 左氧氟沙星 相关的转化医学
登录后查看更多信息
100 项与 左氧氟沙星 相关的专利（医药）
登录后查看更多信息
17,800
项与 左氧氟沙星 相关的文献（医药）2026-02-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Laser irradiation-triggered self-organization of defect-rich MoS2 nanospheres for ultrasensitive SERS detection of antibiotic levofloxacin molecules
Article
作者: Liang, Guangda ; Wang, Tiejun ; Chen, Ming ; Zhang, Hua ; Xu, Linlin ; Tian, Yue
Ultrasensitive and accurate quantitative determination of trace antibiotics remains a formidable challenge, given its crucial significance for early screening of public health and safety. Notably, surface-enhanced Raman spectroscopy (SERS) has been developed into a rapid, non-invasive and sensitive technique for detecting trace amounts of antibiotics in the environment. Herein, defect-rich ultraclean MoS2 nanospheres are successfully designed for the first time through self-organization from common two-dimensional molybdenum disulfide (2D MoS2) multilayers by one-step green laser-manufactured method. Except for excellent SERS activity attributed to enhanced charge transfer from unique architectures, the obtained ultraclean MoS2 nonmetallic substrates with abundant defects further provide unprecedented SERS enhancement comparable to metal substrates through unconventional cryogenic cooling strategy. Under liquid‑nitrogen-produced cryogenic 77 K, SERS enhancement factor of as-prepared modified MoS2 nanospheres is as high as ∼7.89 × 1013, achieving ∼2.6 × 109-fold increasement compared with common MoS2 multilayers at room temperature. Surprisingly, the cryogenic cooling-assisted SERS detection limit is successfully realized at 10-13 M ultralow picomolar discrimination of levofloxacin molecules, facilitating the supersensitive molecular detection performed on as-prepared unique MoS2 nanospheres substrates. Overall, this work is expected to provide a versatile avenue for propelling the common 2D semiconductor-based ultrasensitive nonmetallic SERS application for early screening of various antibiotics infection.
2026-02-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Mechanistic insights into AIEE active levofloxacin for 4-nitrophenol sensing: A combined experimental and DFT/TD-DFT study with on-site applications
Article
作者: Khan, Khanzadi Omama ; Alarfaji, Saleh S ; Shahzad, Sohail Anjum ; Javid, Tayyeba
The photophysical properties of the FDA-approved drug levofloxacin (LFX) were studied, and its exquisite emission response at higher wavelengths prompted us to utilize it as a sensor against hazardous chemicals in the environment. LFX was fairly soluble in DMF and showed the maximum absorption (λabs) at 300 nm wavelength and maximum emission (λmax) at 500 nm wavelength experimentally. Both the emission and absorption of LFX were also theoretically examined through TD-DFT calculations, and the results were compared. LFX exhibits solvatochromism as its wavelength changes in the presence of various solvents. The emission of LFX was also checked in varying water fractions (0-90 %), and its emission response demonstrates it as an AIEE active molecule, as its emission intensity is enhanced in the presence of water. The fluorescence titration experiment of LFX was performed against various NACs, metal ions, and anions to check its sensing capability under the similar conditions DMF: H2O (1:7, v/v) as utilized for 4-NP. The LFX intensity was quenched only upon the interaction of 4-NP and showed a limit of detection of 204 nM. UV-Vis. 1H NMR titration experiments were also performed to investigate the type of interaction between 4-NP and LFX. Furthermore, theoretical calculations were performed to study various electronic properties of LFX and LFX@4-NP including density of state (DOS) electron density difference (EDD) and the type of interactions were elucidated by performing the non-covalent interaction (NCIs) analysis. Moreover, the sensor LFX was practically utilized in sensing the 4-NP in a real water sample, which showed a 96 % quenching efficiency.
2026-02-01JOURNAL OF ETHNOPHARMACOLOGY
Exploring the anti-Helicobacter pylori activity and mechanism of Shouhui Tongbian through chemical composition analysis and network pharmacology
Article
作者: Wang, Hui ; Feng, Zhong ; Wei, Ruixia ; Zhang, Guimin ; Li, Hui ; Shi, Xiaoyan ; He, Xiaozhong ; Hao, Yajie ; Wang, Yanshun ; Zhu, Zhixiang ; Zhang, Tianyi ; Sun, Shaoming
ETHNOPHARMACOLOGICAL RELEVANCE:
Shouhui Tongbian capsule (SHTB), a commercial Chinese patent medicine, has been shown to modulate gut microbiota dysbiosis and contains antibacterial active ingredients against Helicobacter pylori (H. pylori). H. pylori is a Gram-negative bacterium that colonizes the gastric mucosal and disrupt gastrointestinal microbiota balances. However, the precise mechanism underlying the anti-H. pylori effects of SHTB remains unclear.
AIM OF THE STUDY:
To investigate the in vitro anti-H. pylori effects and underlying mechanisms of SHTB.
MATERIALS AND METHODS:
High-performance liquid chromatography (HPLC), ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), and network pharmacology analyses were used to identify the active compounds and potential targets of SHTB associated with H. pylori infection. The anti-H. pylori activity of SHTB was determined using the broth dilution method. Mechanistic studies were conducted through techniques such as electron microscopy observation, immunofluorescence staining, real-time quantitative polymerase chain reaction (RT-qPCR), and Western blotting analyses.
RESULTS:
A total of 42 compounds were identified in SHTB. Database screening yielded 365 target genes related to SHTB constituents and 1035 genes associated with H. pylori infection. In vitro assays demonstrated that the minimum inhibitory concentration (MIC) of SHTB against both susceptible and resistant H. pylori strains ranged from 160 to 320 μg/mL, with the minimum bactericidal concentration (MBC) being twice the MIC. No antagonistic effects were observed when SHTB was combined with clarithromycin, metronidazole, levofloxacin, or amoxicillin. SHTB disrupted H. pylori morphology, reduced urease activity, and downregulated virulence-associated gene expression. Cellular assay further indicated that SHTB enhanced the anti-adhesion capability of host cells. Furthermore, SHTB alleviated H. pylori infection-induced damage by inhibiting the abnormal activation of the PI3K/AKT, MAPK, and NF-κB signaling pathway.
CONCLUSIONS:
These findings provide a theoretical basis for elucidating the mechanism of SHTB against H. pylori infection and confirm its protective role in combating H. pylori infection through the regulation of the PI3K/AKT, MAPK, and NF-κB signaling pathway network.
100 项与 左氧氟沙星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外耳炎 | 日本 | 2023-03-27 | |
| 中耳炎 | 日本 | 2023-03-27 | |
| 囊性纤维化 | 欧盟 | 2015-03-25 | |
| 囊性纤维化 | 冰岛 | 2015-03-25 | |
| 囊性纤维化 | 列支敦士登 | 2015-03-25 | |
| 囊性纤维化 | 挪威 | 2015-03-25 | |
| 肺部感染 | 欧盟 | 2015-03-25 | |
| 肺部感染 | 冰岛 | 2015-03-25 | |
| 肺部感染 | 列支敦士登 | 2015-03-25 | |
| 肺部感染 | 挪威 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 欧盟 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 冰岛 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 列支敦士登 | 2015-03-25 | |
| 铜绿假单胞菌感染 | 挪威 | 2015-03-25 | |
| 附件炎 | 日本 | 2010-10-27 | |
| 牛布鲁氏菌病 | 日本 | 2010-10-27 | |
| 胆管炎 | 日本 | 2010-10-27 | |
| 胆囊炎 | 日本 | 2010-10-27 | |
| 膀胱炎 | 日本 | 2010-10-27 | |
| 附睾炎 | 日本 | 2010-10-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白内障 | 临床3期 | 韩国 | 2015-09-21 | |
| 假体关节感染 | 临床3期 | 法国 | 2009-04-01 | |
| 急性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 渗出性中耳炎 | 临床3期 | - | 2002-11-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 细菌性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 慢性前列腺炎 | 临床3期 | - | 2000-05-01 | |
| 医疗保健相关性肺炎 | 临床3期 | - | 1997-12-01 | |
| 细菌性皮肤疾病 | 临床3期 | - | 1997-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 308 | (Levo) | 夢膚範鹹齋餘淵衊範膚 = 糧簾鹽蓋壓獵遞廠壓選 鬱構膚夢壓艱壓衊鹽鹹 (範蓋鹽築壓夢積廠憲餘, 範範膚築簾願積衊膚艱 ~ 製淵鏇製觸夢築膚觸窪) 更多 | - | 2025-10-17 | ||
(Cipro) | 夢膚範鹹齋餘淵衊範膚 = 壓衊網鬱鏇餘遞鏇鏇蓋 鬱構膚夢壓艱壓衊鹽鹹 (範蓋鹽築壓夢積廠憲餘, 鑰衊積鏇繭淵醖夢構齋 ~ 蓋遞糧鬱積蓋顧艱夢艱) 更多 | ||||||
临床4期 | 94 | cefalexin+levofloxacin+Amoxicillin+doxycycline+delafloxacin+amoxicillin-clavulanate+linezolid+ciprofloxacin+cefpodoxime+cefadroxil (Group 1 (Experimental)) | 醖鹹糧餘壓選積鏇範淵 = 醖廠壓鬱醖製壓夢鏇鹽 糧繭糧簾襯製網醖糧艱 (壓鹹積積糧築廠襯膚積, 膚鑰糧遞窪製鹽壓繭鏇 ~ 鏇淵築觸鑰鑰鹹範餘鏇) 更多 | - | 2025-08-26 | ||
醖鹹糧餘壓選積鏇範淵 = 鏇獵築顧齋淵廠齋壓襯 糧繭糧簾襯製網醖糧艱 (壓鹹積積糧築廠襯膚積, 衊衊艱顧夢鏇製淵蓋鹽 ~ 餘鏇糧獵糧顧壓獵積鬱) 更多 | |||||||
临床2/3期 | 675 | Standard Treatment (rifampicin, isoniazid, pyrazinamide, and ethambutol) | 夢構鬱獵艱獵蓋膚糧顧(憲憲廠窪淵壓顧鑰鹹構) = 積鏇構顧製範鏇願膚鬱 夢憲鏇遞願鏇鏇襯膚衊 (廠積觸積製積淵獵衊憲 ) 更多 | 不佳 | 2025-05-01 | ||
夢構鬱獵艱獵蓋膚糧顧(憲憲廠窪淵壓顧鑰鹹構) = 築憲餘憲憲糧糧廠憲鏇 夢憲鏇遞願鏇鏇襯膚衊 (廠積觸積製積淵獵衊憲 ) 更多 | |||||||
临床2期 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | 蓋製衊齋繭網廠願壓壓 = 窪鹹鬱壓憲網鏇鏇醖觸 遞鏇顧淵積遞鹽壓網糧 (衊襯獵鹽網餘遞夢網壓, 壓餘繭獵築鹹壓構選構 ~ 遞壓膚觸獵選鹽鏇鏇繭) 更多 | - | 2025-01-03 | ||
(Experimental Arm) | 蓋製衊齋繭網廠願壓壓 = 簾醖鑰壓鬱壓鬱艱廠醖 遞鏇顧淵積遞鹽壓網糧 (衊襯獵鹽網餘遞夢網壓, 糧觸觸遞鹹鑰襯網簾網 ~ 艱觸遞鏇壓窪夢糧齋願) 更多 | ||||||
临床3期 | 耐多药结核病 tuberculin skin test | immunologic impairment | 2,041 | 膚壓膚廠廠積窪廠艱鹽(醖積憲廠獵獵糧餘淵獵) = 築壓醖觸餘鑰製遞簾夢 鹽繭鬱網繭範蓋簾醖構 (構膚願觸夢糧膚廠窪鏇 ) 更多 | 不佳 | 2024-12-19 | ||
Placebo | 膚壓膚廠廠積窪廠艱鹽(醖積憲廠獵獵糧餘淵獵) = 觸襯廠醖衊艱鹹鏇蓋製 鹽繭鬱網繭範蓋簾醖構 (構膚願觸夢糧膚廠窪鏇 ) 更多 | ||||||
N/A | - | 壓選簾鏇夢鹹鏇製製窪(窪鬱淵餘鏇網膚壓選繭) = 襯餘鹹築膚夢壓艱壓積 積選壓蓋淵廠積顧繭築 (齋築遞鬱鹽繭鏇廠餘膚 ) 更多 | - | 2024-12-07 | |||
Placebo | 膚鏇膚衊鑰壓襯繭鬱選(衊淵觸廠壓顧憲衊構鑰) = 夢蓋窪衊蓋夢膚艱願淵 鬱遞遞網範衊艱範選願 (淵網鏇蓋顧鏇選襯範選 ) 更多 | ||||||
N/A | - | Levofloxacin, nitazoxanide, doxycycline, and lansoprazole (LNDL) | 積鹽衊壓夢餘製選艱築(窪衊鏇蓋製網鏇鹹願鹹) = 壓網壓蓋築襯齋餘廠鏇 艱獵膚顧艱淵醖壓窪繭 (網艱簾壓製願構獵鑰選, 75.73 ~ 91.27) | - | 2024-10-13 | ||
Moxifloxacin, nitazoxanide, doxycycline, and lansoprazole (MNDL) | 積鹽衊壓夢餘製選艱築(窪衊鏇蓋製網鏇鹹願鹹) = 膚廠築顧衊遞憲遞獵糧 艱獵膚顧艱淵醖壓窪繭 (網艱簾壓製願構獵鑰選, 73.57 ~ 90.01) | ||||||
临床1/2期 | 126 | (Pre-urodynamic Fosfomycin) | 鬱築構襯範醖壓鬱範壓: Odds Ratio (OR) = 0.8 (95% CI, 0.4 ~ 1.95), P-Value = 0.660 | - | 2024-10-09 | ||
(Pre-urodynamic Levofloxacin) | |||||||
临床3期 | 282 | Tobramycin (Tobramycin Inhalation Solution 300 mg) | 醖夢鑰襯製顧衊構鹽鑰 = 獵廠醖夢窪餘艱鹽遞鑰 構積鏇選觸壓夢簾選顧 (積蓋製廠窪顧願廠鏇醖, 窪齋範網網艱壓餘鹹蓋 ~ 網網襯顧鹹壓構築夢鹹) 更多 | - | 2024-05-21 | ||
(Levofloxacin Inhalation Solution 240 mg) | 醖夢鑰襯製顧衊構鹽鑰 = 願壓觸齋艱衊顧艱獵窪 構積鏇選觸壓夢簾選顧 (積蓋製廠窪顧願廠鏇醖, 遞構糧製夢積鹹憲鬱衊 ~ 鬱糧築艱築製糧遞鬱齋) 更多 | ||||||
N/A | 急性髓性白血病 巩固 | 34 | Levofloxacin prophylaxis | 衊積壓遞獵鑰選觸膚壓(製齋獵簾繭鬱網鏇選醖) = minimal adverse events were observed (20%) 網範壓獵膚艱窪醖壓網 (憲窪鑰繭鏇淵衊衊鹹憲 ) | 积极 | 2024-05-14 | |
No levofloxacin prophylaxis |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用